ONCO Onconetix Inc

As filed with the Securities and Exchange Commission on November 1, 2024

Registration No. 333-             

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

FORM S-1

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

 

Onconetix, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware		2834		83-2262816
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification No.)

 

201 E. Fifth Street, Suite 1900
Cincinnati, Ohio 45202
Telephone: (513) 620-4101
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

Karina M. Fedasz
Interim Chief Financial Officer
201 E. Fifth Street, Suite 1900
Cincinnati, Ohio 45202
Telephone: (513) 620-4101
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

 

with copies to:

Barry I. Grossman, Esq.
Jessica Yuan, Esq.
Ellenoff Grossman & Schole LLP
1345 Avenue of the Americas
New York, NY 10105
Phone: (212) 370-1300
Fax: (212) 370-7889

 

Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said Section 8(a), may determine.

 

 

 

The information in this prospectus is not complete and may be changed. The Selling Stockholders named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.

 

PROSPECTUS

SUBJECT TO COMPLETION

DATED NOVEMBER 1, 2024

 

10,586,556 Shares of Common Stock

 

 

This prospectus relates to the resale by Selling Stockholders of 10,586,556 shares of common stock of Onconetix, Inc. (“we,” “us,” “our,” the “Company,” or “Onconetix”), par value $0.00001 per share (the “Common Stock”), by the Selling Stockholders listed in this prospectus or their permitted transferees (the “Selling Stockholders”). The shares of Common Stock registered for resale pursuant to this prospectus include:

 

●

559,397 shares of Common Stock  issuable upon exercise of common stock preferred investment options (the “Inducement PIOs”) issued to Armistice Capital Master Fund Ltd. (“Armistice”) and Sabby Volatility Warrant Master Fund, Ltd (“Sabby”) in a warrant inducement transaction (the “Warrant Inducement”), which closed on July 15, 2024;

 

●

13,054 shares of Common Stock issuable upon exercise of common stock preferred investment options issued to H.C. Wainwright & Co., LLC (“Wainwright”), the Company’s placement agent for the Warrant Inducement, or its designees, on July 15, 2024 in the Warrant Inducement (the “Placement Agent Inducement PIOs” and, together with the Inducement PIOs, the “PIOs”);

 

●

130,321 shares of Common Stock, out of an aggregate of 142,749 shares issued to Veru Inc. (“Veru”) following Veru’s election to convert all of the 3,000 shares of Series A preferred stock (“Series A Preferred Stock”) of the Company issued to it on September 29, 2023;

 

●

6,464,205 shares of Common Stock, out of an aggregate of 6,741,820 shares issued to certain stockholders of the Company (the “PMX Converted Shares”) who were formerly holders of outstanding capital stock or convertible securities (the “Sellers”) of Proteomedix AG (“Proteomedix”), pursuant to the automatic conversion of all the 2,696,729 shares of Series B preferred stock (“Series B Preferred Stock”) of the Company on September 24, 2024;

 

●

667,451 shares of Common Stock issued to Altos Venture AG, in a private placement transaction and a warrant exercise, which closed on September 24, 2024;

 

●

up to 2,752,128 shares of Common Stock, which represents 150% of the aggregate number of shares of Common Stock issuable upon the conversion or exercise, as applicable, of the 3,499 shares of Series C preferred stock (the “Series C Preferred Stock”) and warrants to purchase 591,856 shares of Common Stock (the “PIPE Warrants”) issued to institutional investors in a private placement transaction, which closed on October 2, 2024.

 

The Inducement PIOs have an initial exercise price of $6.00 per share, subject to adjustment; one-third of such preferred investment options will expire five years from the date of stockholder approval (September 5, 2024), and the remaining two-thirds will expire twenty-four months from such date. The Placement Agent Inducement PIOs have an initial exercise price of $7.50 per share, subject to adjustment, and will expire five years from the issuance date. The PIPE Warrants have an initial exercise price of $4.38, subject to adjustment, and will expire three years from the Initial Exercisability Date (as defined below). The conversion price of the Series C Preferred Stock is $4.5056, subject to adjustment as provided in the Certificate of Designations. 

 

 

We are registering the above-referenced shares on behalf of the Selling Stockholders, to be offered and sold by them from time to time. We are not selling any securities under this prospectus. We will receive the proceeds from any exercise of the PIOs or the PIPE Warrants for cash, but not from the net exercise of any PIOs or PIPE Warrants on a cashless basis or from the resale of any shares of Common Stock by the Selling Stockholders pursuant to this prospectus or the sale of the shares of Common Stock issuable upon the exercise of the PIOs or the PIPE Warrants.

 

Our Common Stock is listed on The Nasdaq Capital Market under the symbol “ONCO.” The last reported sale price of our Common Stock on The Nasdaq Capital Market on October 30, 2024 was $2.96 per share. We recommend that you obtain current market quotations for our Common Stock prior to making an investment decision.

 

The Selling Stockholders may offer all or part of the shares for resale from time to time through public or private transactions, at either prevailing market prices or at privately negotiated prices. Our registration of the shares of Common Stock covered by this prospectus does not mean that the Selling Stockholders will offer or sell any of the shares. With regard only to the shares the Selling Stockholders sell for their own behalf, the Selling Stockholders may be deemed an “underwriter” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). The Company has paid all of the registration expenses incurred in connection with the registration of the shares. We will not pay any of the selling commissions, brokerage fees and related expenses.

 

We will pay the expenses incurred in registering the shares, including legal and accounting fees. See “Plan of Distribution” on page 23 of this prospectus.

 

Investing in our Common Stock involves certain risks. See “Risk Factors” on page 7 of this prospectus, included in any accompanying prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.

 

We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire prospectus, any amendments or supplements, any free writing prospectuses, and any documents incorporated by reference carefully before you make your investment decision.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

 

The date of this prospectus is                     , 2024

 

 

TABLE OF CONTENTS

 

		Page
ABOUT THIS PROSPECTUS		ii
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS		iii
RISK FACTORS		7
PIPE FINANCING		10
DESCRIPTION OF CAPITAL STOCK		17
SELLING STOCKHOLDERS		19
PLAN OF DISTRIBUTION		23
EXPERTS		25
LEGAL MATTERS		25
WHERE YOU CAN FIND MORE INFORMATION		25

 

 

ABOUT THIS PROSPECTUS

 

This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process for the delayed or continuous offering and sale of securities pursuant to Rule 415 under the Securities Act. This prospectus generally describes Onconetix, Inc. and our Common Stock. The Selling Stockholders may use the shelf registration statement to sell up to an aggregate of up to 10,586,556 shares of our Common Stock from time to time through any means described in the section entitled “Plan of Distribution.”

 

We will receive the proceeds from any exercise of the PIOs or the PIPE Warrants for cash, but not from the net exercise of any PIOs or PIPE Warrants on a cashless basis or from the resale of any shares of Common Stock by the Selling Stockholders pursuant to this prospectus or the sale of the shares of Common Stock issuable upon the exercise of the PIOs or the PIPE Warrants. However, we will pay the expenses, other than underwriting discounts and commissions, associated with the sale of shares pursuant to this prospectus.

 

We and the Selling Stockholders, as applicable, may deliver a prospectus supplement with this prospectus, to the extent appropriate, to update the information contained in this prospectus. The prospectus supplement may also add, update or change information included in this prospectus. You should read both this prospectus and any applicable prospectus supplement, together with additional information described below under the captions “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.”

 

No offer of these securities will be made in any jurisdiction where the offer is not permitted.

 

You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates.

 

Unless the context otherwise indicates, references in this prospectus to “we,” “our” and “us” refer, collectively, to Onconetix, Inc., a Delaware corporation.

 

Unless otherwise indicated, all share amounts and share prices disclosed herein are presented on a post-split basis, giving effect to the one-for-forty (1:40) reverse stock split (the “Reverse Stock Split”) of all of the outstanding shares of the Company’s issued and outstanding Common Stock on September 24, 2024. As the financial statements incorporated by reference in this prospectus were filed prior to the Reverse Stock Split, the outstanding shares disclosed in such financial statements are presented on a pre-split basis. Future financial statements filed by the Company retrospectively present the shares on a post-split basis.

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus contains “forward-looking statements” within the meaning of the federal securities laws, and that involve significant risks and uncertainties. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Forward-looking statements are subject to a number of risks, uncertainties and assumptions in other documents we file from time to time with the SEC, specifically our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K.

 

Important factors that could cause such differences include, but are not limited to:

 

●

our projected financial position and estimated cash burn rate;

 

●

our estimates regarding expenses, future revenues and capital requirements;

 

●

our ability to continue as a going concern;

 

●

our need to raise substantial additional capital to fund our operations;

 

●

our ability to commercialize or monetize Proclarix and integrate the assets and commercial operations acquired in the share exchange with Proteomedix AG (“Proteomedix”);

 

●

our reliance on third parties, including Labcorp, to develop, market, distribute and sell our products;

 

●

the successful development of our commercialization capabilities, including sales and marketing capabilities.

 

●

our ability to obtain and maintain the necessary regulatory approvals to market and commercialize our products;

 

●

the results of market research conducted by us or others;

 

●

our ability to obtain and maintain intellectual property protection for our current products;

 

●

our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights;

 

●

the possibility that a third party may claim we or our third-party licensors have infringed, misappropriated, or otherwise violated their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against claims against us;

 

●

our reliance on third parties, including manufacturers and logistics companies;

 

●

the success of competing therapies or diagnostics and products that are or become available;

 

●

our ability to successfully compete against current and future competitors;

 

●

our ability to expand our organization to accommodate potential growth and our ability to attract, motivate and retain key personnel;

 

 

●

the potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for these product liability lawsuits to cause us to limit our commercialization of our products;

 

●

market acceptance of our products, the size and growth of the potential markets for our current products, and our ability to serve those markets; and

 

●

disruptions in the business of the Company or Proteomedix, which could have an adverse effect on their respective businesses and financial results.

 

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors.” Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations.

 

You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus forms a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

 

 

RISK FACTORS

 

Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described in this prospectus, in our most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, before making an investment decision pursuant to this.

 

Our business, financial condition and results of operations could be materially and adversely affected by any or all of these risks or by additional risks and uncertainties not presently known to us or that we currently deem immaterial that may adversely affect us in the future.

 

Risks Related to This Offering

 

Sales of a substantial number of our securities in the public market by the Selling Stockholders and/or by our existing securityholders could cause the price of our shares of Common Stock to fall.

 

The Selling Stockholders can sell, under this prospectus, up to 10,586,556 shares of Common Stock. The sale of all or a portion of the securities being offered in this prospectus, or the perception that those sales might occur, could depress the market price of our Common Stock, and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our Common Stock.

 

Issuances of shares of our Common Stock upon exercise of the PIPE Warrants or conversion of Series C Preferred Stock would result in substantial dilution of our stockholders and may have a negative impact on the market price of our Common Stock.

 

The shares of Common Stock issuable pursuant to the PIPE Warrants and the Series C Preferred Stock, to the extent exercised or converted, respectively, would impose significant dilution on our stockholders and may have a negative impact on the market price of our Common Stock.

 

Additionally, each of the PIPE Warrants and the Certificate of Designations for the Series C Preferred Stock provide that if the Company issues (subject to certain exceptions) (i) any shares of Common Stock, (ii) any options to purchase Common Stock or (iii) any convertible securities, for a consideration price per share or exercise or conversion price per share, as applicable, less than the exercise price of the PIPE Warrants or the conversion price of the Series C Preferred Stock, respectively, in effect immediately prior to such issuance, the exercise price and conversion price shall be reduced accordingly.

 

We may use proceeds from any exercise of the PIOs or the PIPE Warrants for cash in ways with which you may not agree or in ways which may not yield a significant return.

 

We will have broad discretion over the use of proceeds from any exercise of the PIOs or the PIPE Warrants for cash, including for any of the purposes described in the section entitled “Use of Proceeds,” and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds, their ultimate use may vary substantially from their currently intended use. While we expect to use the net proceeds from this offering as set forth in “Use of Proceeds,” we are not obligated to do so. The failure by us to apply these funds effectively could harm our business, and the net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value of our Common Stock.

 

Other Risks

 

There is substantial doubt about our ability to continue as a “going concern,” and we will require substantial additional funding to finance our long-term operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate some or all of our products and operations.

 

The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of June 30, 2024, the Company had cash of approximately $0.9 million, a working capital deficit of approximately $18.6 million and an accumulated deficit of approximately $82.2 million. In addition, as of October 30, 2024, the Company’s cash balance was approximately $595,000, and the Company has $5.0 million of debt, plus interest, due in each of March 2025 and June 2025.

 

 

We estimate, as of the date of this prospectus, that our current cash balance is only sufficient to fund our operations into November 2024. We believe that we will need to raise substantial additional capital to fund our continuing operations, satisfy existing and future obligations and liabilities, and otherwise support the Company’s working capital needs and business activities, including making the remaining payments to Veru and the development and commercialization of Proclarix. Management’s plans include generating product revenue from sales of Proclarix, which is still subject to further successful commercialization activities within certain jurisdictions. In addition, the Company has now abandoned commercialization activities for ENTADFI and it is exploring strategic alternatives for its monetization, such as a potential sale of the ENTADFI assets. If we are not able to consummate a sale or other transaction of the ENTADFI assets, we may abandon the assets and destroy our inventory of the product. Management’s plans also include attempting to secure additional required funding through equity or debt financings if available. However, there are currently no commitments in place for further financing nor is there any assurance that such financing will be available to the Company on favorable terms, if at all. If the Company is unable to secure additional capital, it may be required to delay or curtail any future commercialization of products, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations, or, if it is required to, file for bankruptcy. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of time within one year from the issuance of the condensed consolidated financial statements.

 

Our future capital requirements will depend on many factors, including:

 

●

the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties and distribution, for Proclarix and other products for which we have received or will receive marketing approval;

  

●

our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement;

 

●

any product liability or other lawsuits related to our products;

 

●

the expenses needed to attract, hire, and retain skilled personnel;

 

●

the revenue, if any, received from commercial sales of Proclarix or other products for which we may receive marketing approval;

 

●

the costs to establish, maintain, expand, enforce, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending, and enforcing our patents or other intellectual property rights; and

 

●

the costs of operating as a public company.

 

Our ability to raise additional funds will depend on financial, economic, and other factors, many of which are beyond our control. We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be forced to delay, reduce or terminate our business activities.

 

 

Our current liabilities are significant, and if those to whom we owe accounts payable, such as Veru, IQVIA or other creditors or vendors, were to demand payment, we would be unable to pay.

 

As of June 30, 2024, we had total current liabilities of approximately $20.6 million, including accounts payable of approximately $3.2 million, accrued expenses of approximately $1.4 million, and related party subscription liability of $0.9 million. As of October 30, 2024, the Company’s cash balance was approximately $595,000, and the Company has $5.0 million of debt, plus interest, due in each of March 2025 and June 2025. We are currently considering strategic options for ENTADFI, including a potential sale or abandonment, and plan to seek funding to support our operations. However, the level of our current liabilities may make it more difficult for us to obtain adequate financing on favorable terms, if at all. If those to whom these payments are due were to demand immediate payment, as they are entitled to do, and we are not able to make the required payments, we would be subject to liability if our creditors chose to enforce their rights, which could result in our bankruptcy and insolvency. Under such a scenario, our assets would be distributed to our creditors, leaving nothing to be distributed to our stockholders.

 

We are dependent on third parties, including Labcorp, to develop, market, distribute and sell our products.

 

Our ability to receive revenues is dependent upon the sales and marketing efforts of co-marketing partners and third-party distributors. In particular, the development and commercialization of Proclarix in the United States is being pursued by Labcorp, pursuant to an exclusive license agreement that grants Labcorp the exclusive right to develop and commercialize Proclarix, and other products developed by Labcorp using Proteomedix’s intellectual property covered by the license, in the United States for identification, screening, staging, predisposition, diagnosis, prognosis, monitoring, prevention or treatment selection with respect to prostate cancer. However, we do not have control over Labcorp’s development and commercialization of Proclarix, and there can be no guarantee that Labcorp will continue to advance development and commercialization efforts, or that Labcorp will successfully commercialize Proclarix in the United States.

 

Labcorp may terminate or seek to renegotiate the terms of this agreement, which could adversely affect our business operations and financial condition. If Labcorp terminates the agreement or demands terms that are less favorable to us, we may experience disruptions in our product development and commercialization efforts, potentially leading to a loss of revenue and market share.

 

Additionally, if Labcorp is unable to commercialize Proclarix in the United States, and we fail to reach an agreement with any other commercialization partner, or upon reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative impact on our business, financial condition, and results of operations.

 

 

PIPE FINANCING

 

On October 2, 2024, the Company entered into, and sold to the PIPE Investors, pursuant to the Securities Purchase Agreement an aggregate of 3,499 shares of Series C Preferred Stock, which includes an issuance of 830 shares of Series C Preferred Stock to the lead investor as consideration for the PIPE Investors’ irrevocable commitment to purchase shares of the Series C Preferred Stock, and 591,856 PIPE Warrants, for aggregate cash proceeds to the Company of $2.0 million. Concurrently with entering into the Securities Purchase Agreement, the Company also entered into a registration rights agreement with the PIPE Investors, pursuant to which it has agreed to provide the PIPE Investors with certain registration rights related to the shares of Common Stock underlying the PIPE Securities.

 

The material terms of the Series C Preferred Stock and the PIPE Warrants are set forth below.

 

Series C Preferred Stock

 

Certificate of Designations

  

General. Pursuant to the Certificate of Designations, the Company has authorized the issuance of up to 10,000 shares of Series C Preferred Stock, each having a stated value of $1,000 per share (the “Stated Value”). The Company has issued 3,499 shares of the Company Series C Preferred Stock to the PIPE Investors.

 

Ranking.  Except (i) for the Series A Preferred Stock of the Company (of which there are no shares currently outstanding), which shall be Parity Stock, and (ii) to the extent that the Required Holders (as defined in the Securities Purchase Agreement) expressly consent to the creation of Parity Stock or Senior Preferred Stock, all shares of capital stock of the Company will be junior in rank to all Preferred Shares with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company.

 

Dividends. The holders of Series C Preferred Stock are entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends actually paid on shares of Common Stock, when and if actually paid. In addition, from and after the occurrence and during the continuance of any Triggering Event, dividends (“Default Dividends”) will accrue on the Stated Value of each Preferred Share at a rate of fifteen percent (15.0%) (the “Default Rate”) per annum. Default Dividends are payable by way of inclusion of Default Dividends in the Conversion Amount (as defined below) on each Conversion Date, upon any redemption or upon any required payment upon any Bankruptcy Triggering Event. In the event that such Triggering Event is subsequently cured (and no other Triggering Event then exists), the accrual of Default Dividends will cease to be effective as of the calendar day immediately following the date of such cure; provided that Default Dividends as calculated and unpaid during the continuance of such Triggering Event will continue to apply to the extent relating to the days after the occurrence of such Triggering Event through and including the date of such cure of such Triggering Event. 

 

Conversion Rights:

 

Conversion at Option of Holder.  Each holder is entitled to convert any portion of the outstanding Preferred Shares held by such holder into validly issued, fully paid and non-assessable Conversion Shares at the Conversion Rate. Except as otherwise provided in the Certificate of Designations, the number of Conversion Shares issuable upon conversion of any Preferred Share will be determined by dividing (x) the Conversion Amount of such Preferred Share by (y) the Conversion Price (the “Conversion Rate”). As used herein, the term “Conversion Amount” means, with respect to each Preferred Share, as of the applicable date of determination, the sum of (1) the Stated Value thereof plus (2) any Default Dividends thereon as of such date of determination plus (3) any other amounts owed to such PIPE Investor pursuant to the terms of the Certificate of Designations or any other Transaction Document; and the term “Conversion Price” means, with respect to each Preferred Share, as of any Conversion Date or other date of determination, $4.5056, subject to adjustment as provided in the Certificate of Designations.

 

Conversion at the Option of the Holder Upon the Occurrence of a Triggering Event. After the Stockholder Approval Date (as defined in the Securities Purchase Agreement), if a Triggering Event occurs and is continuing, at any time after the earlier of a holder’s receipt of a Triggering Event Notice and such holder becoming aware of such Triggering Event (such earlier date, the “Alternate Conversion Right Commencement Date”) and ending on the twentieth (20^th) Trading Day after the later of (x) the date such Triggering Event is cured and (y) such holder’s receipt of a Triggering Event Notice (such ending date, the “Alternate Conversion Right Expiration Date”, and each such period, an “Alternate Conversion Right Period”), such holder may, at such holder’s option, by delivery of a Conversion Notice to the Company (the date of any such Conversion Notice, each an “Alternate Conversion Date”), convert all, or any number of Preferred Shares held by such holder into shares of Common Stock at the Alternate Conversion Price (each, an “Alternate Conversion”).

 

 

As used herein:

 

“Alternate Conversion Price” means, with respect to any Alternate Conversion that price which will be the lowest of (i) the applicable Conversion Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, and (ii) the greater of (x) the Floor Price and (y) 80% of the lowest VWAP of the Common Stock during the five (5) consecutive Trading Day period ending and including the Trading Day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice (such period, the “Alternate Conversion Measuring Period”). All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion Measuring Period.

 

“Alternate Conversion Floor Amount” means an amount equal to the product obtained by multiplying (A) the higher of (i) the highest price that the Common Stock trades at on the Trading Day immediately preceding the relevant Alternate Conversion Date and (ii) the applicable Alternate Conversion Price and (B) the difference obtained by subtracting (i) the number of shares of Common Stock delivered (or to be delivered) to such holder on the applicable Share Delivery Deadline with respect to such Alternate Conversion from (ii) the quotient obtained by dividing (x) the applicable Conversion Amount that such holder has elected to be the subject of the applicable Alternate Conversion, by (y) the applicable Alternate Conversion Price, without giving effect to the Floor Price.

 

“Floor Price” means $1.00 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events), or, subject to the rules and regulations of the Principal Market, such lower price as the Company and the Required Holders may agree, from time to time.

 

“Triggering Event Notice” means written notice from the Company delivered to each holder within two Business Days after the occurrence of a Triggering Event) that includes (i) a reasonable description of the applicable Triggering Event, (ii) a certification as to whether, in the reasonable opinion of the Company, such Triggering Event is capable of being cured and, if applicable, a reasonable description of any existing plans of the Company to cure such Triggering Event and (iii) a certification as to the date the Triggering Event occurred and, if cured on or prior to the date of such Triggering Event Notice, the applicable Alternate Conversion Right Expiration Date.

   

“Triggering Event” includes, but is not limited to, the following, subject to certain cure periods as set forth in the Certificate of Designations:

 

(i) the failure to file a registration statement for the resale of the shares of Common Stock underlying the Preferred Shares and the PIPE Warrants, or the failure of the applicable Registration Statement to be declared effective by the SEC, ten (10) days after the applicable deadline;

 

(ii) the failure to maintain the effectiveness of a registration statement pursuant to the terms of the Registration Rights Agreement;

 

(iii) the suspension from trading or the failure of the Common Stock to be trading or listed (as applicable) on an Eligible Market for a period of five (5) consecutive Trading Days;

 

(iv) failure to cure a Conversion Failure or a Delivery Failure (as defined in the PIPE Warrants) by delivery of the required number of shares of Common Stock within the requisite time frame;

 

(v) failure to maintain authorized, but unissued shares equal to 150% of the shares underlying the Preferred Shares and the PIPE Warrants;

 

(vi) the occurrence of any default under, redemption of or acceleration prior to maturity of at least an aggregate of $500,000 of Indebtedness of the Company or any of its Subsidiaries, or a final judgment or judgments for the payment of money aggregating in excess of $500,000 are rendered against the Company and/or any of its Subsidiaries;

 

 

(vii) the institution, commencement, court order or decree by or against the Company or any Subsidiary of certain bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors (the “Bankruptcy Triggering Events”);

 

(viii) the Company and/or any Subsidiary, individually or in the aggregate, either (i) fails to pay, when due, or within any applicable grace period, any payment with respect to any Indebtedness in excess of $500,000 due to any third party (other than, with respect to unsecured Indebtedness only, payments contested by the Company and/or such Subsidiary (as the case may be) in good faith by proper proceedings and with respect to which adequate reserves have been set aside for the payment thereof in accordance with GAAP) or is otherwise in breach or violation of any agreement for monies owed or owing in an amount in excess of $500,000, which breach or violation permits the other party thereto to declare a default or otherwise accelerate amounts due thereunder, or (ii) suffer to exist any other circumstance or event that would, with or without the passage of time or the giving of notice, result in a default or event of default under any agreement binding the Company or any Subsidiary, which default or event of default would or is likely to have a material adverse effect on the business, assets, operations (including results thereof), liabilities, properties, condition (including financial condition) or prospects of the Company or any of its Subsidiaries, individually or in the aggregate;

 

(ix) the Company or any Subsidiary breaches any representation or warranty in any material respect (other than representations or warranties subject to Material Adverse Effect or materiality, which may not be breached in any respect) or any covenant or other term or condition of any Transaction Document;

 

(x) a false or inaccurate certification (including a false or inaccurate deemed certification) by the Company that either (A) the Equity Conditions are satisfied, (B) there has been no Equity Conditions Failure, or (C) as to whether any Triggering Event has occurred;

 

(xi) any breach or failure in any respect by the Company or any Subsidiary to comply with any provision of the covenants included in the Certificate of Designations;

 

(xii) any Preferred Shares remain outstanding on or after April 2, 2026;

 

(xiii) any Change of Control occurs without the prior written consent of the Required Holders, which consent will not be unreasonably withheld, conditioned or delayed;

 

(xiv) any Material Adverse Effect occurs; or

 

(xv) any provision of any Transaction Document will at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding on or enforceable against the Company, or the validity or enforceability thereof is contested.

 

Conversion Price Adjustments. If on the ninetieth (90th) calendar day and one hundred eightieth (180) calendar day (each an “Adjustment Date”) following the occurrence of the later of (x) the date that Company stockholders approve the transaction and all securities issuable to the PIPE Investors in connection therewith, as required by Nasdaq (“Stockholder Approval”) and (y) the earlier of (a) the effective date of the registration statement to be filed pursuant to the Registration Rights Agreement and (b) the date that the Series C Preferred Stock is eligible to be resold without restriction under Rule 144 of the Securities Act, as amended (the “Securities Act”), the Conversion Price then in effect is greater than the Market Price then in effect (the “Adjustment Price”), the Conversion Price will automatically lower to the Adjustment Price. As used herein, “Market Price” means, with respect to any Adjustment Date, the greater of (x) the Floor Price and (y) the lowest closing price of the Common Stock on the Principal Market on any Trading Day during the five (5) Trading Day period ended on, and including, the Trading Day ended immediately prior to such applicable Adjustment Date (each, a “Market Price Measuring Period”). All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such applicable Market Price Measuring Period. Only downward adjustments will be made. 

 

 

Share Combination Event Adjustment. In addition to the adjustments set forth above, if at any time and from time to time on or after Stockholder Approval, there occurs any share split, share dividend, share combination recapitalization or other similar transaction involving the Common Stock (each, a “Share Combination Event”, and such date thereof, the “Share Combination Event Date”) and the lowest VWAP during the ten consecutive (10) Trading Day period ending and including the fifth (5) Trading Day immediately preceding the Share Combination Event Date (the “Event Market Price”) (provided if the Share Combination Event is effective after close of trading on the primary Trading Market, then commencing on the next Trading Day which period will be the “Share Combination Adjustment Period”) is less than the Conversion Price then in effect, then at the close of trading on the primary Trading Market on the last day of the Share Combination Adjustment Period, the Conversion Price then in effect on such fifth (5th) Trading Day will be reduced (but in no event increased) to the Event Market Price, but not less than the Floor Price. Notwithstanding the foregoing, if one or more Share Combination Events occur prior to Stockholder Approval being obtained and a reduction of the Conversion Price did not occur, once Stockholder Approval is obtained, the Conversion Price will automatically be reduced to equal the lowest Event Market Price with respect to any Share Combination Event that occurred prior to Stockholder Approval being obtained, but not less than the Floor Price.

 

Adjustments for Dilutive Issuances or Variable Price Securities. If and whenever the Company grants, issues or sells (or enters into any agreement to grant, issue or sell), or pursuant to the provisions of the Certificate of Designations is deemed to have done any of the foregoing, but excluding any Excluded Securities granted, issued or sold or deemed to have been granted, issued or sold, any shares of Common Stock for a consideration price per share (the “New Issuance Price”) less than a price equal to the Conversion Price in effect immediately prior to such granting, issuance or sale (such Conversion Price then in effect is referred to herein as the “Applicable Price”) (the foregoing a “Dilutive Issuance”), then, immediately after such Dilutive Issuance, the Conversion Price then in effect will be reduced to an amount equal to the New Issuance Price.

 

Additionally, if the Company grants, issues or sells (or enters into any agreement to grant, issue or sell) securities that are issuable pursuant to such agreement or convertible into or exchangeable or exercisable for shares of Common Stock at a price which varies or may vary with the market price of the shares of Common Stock, including by way of one or more reset(s) to a fixed price, (each of the formulations for such variable price being herein referred to as, the “Variable Price”), the holder shall have the right, but not the obligation, in its sole discretion to substitute the Variable Price for the Conversion Price.

 

Voluntary Adjustment Right. Subject to the rules and regulations of the Principal Market, the Company has the right, at any time, with the written consent of the Required Holders, to lower the fixed conversion price to any amount and for any period of time deemed appropriate by the Company board of directors.

 

Change of Control Exchange. Upon a change of control of the Company, each holder may require the Company to exchange the holder’s shares of Series C Preferred Stock for consideration equal to the change of Control Election Price, to be satisfied at the Company’s election in either (x) cash or (y) rights convertible into such securities or other assets to which such holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by such holder upon consummation of such corporate event.

  

Fundamental Transactions. The Certificate of Designations prohibits the Company from entering specified fundamental transactions (including, without limitation, mergers, business combinations and similar transactions) unless the Company (or the Company’s successor) assumes in writing all of the Company’s obligations under the of Common Stock, except as provided in the transaction documents in the PIPE Financing.

 

Redemption Rights:

 

Optional Redemption by the Company. At any time, the Company has the right to redeem in cash all, but not less than all, of the Preferred Shares then outstanding at a price (the “Company Optional Redemption Price”) equal to 125% of the greater of (i) the Conversion Amount being redeemed and (ii) the product of (1) the Conversion Rate with respect to the Conversion Amount being redeemed multiplied by (2) the greatest closing sale price of the Company’s Common Stock on any Trading Day during the period commencing on the date immediately preceding the date the Company notifies the holders of its election to redeem and the date the Company makes the entire payment required.

 

 

Mandatory Redemption by the Company Upon a Bankruptcy Triggering Event. Upon the occurrence and continuation of a Bankruptcy Triggering Event, the Company will immediately redeem, in cash, each of the Preferred Shares then outstanding at a redemption price equal to the greater of (i) the product of (A) the Conversion Amount to be redeemed multiplied by (B) 125% and (ii) the product of (X) the Conversion Rate with respect to the Conversion Amount in effect immediately following the date of initial public announcement (or public filing of bankruptcy documents, as applicable) of such Bankruptcy Triggering Event multiplied by (Y) the product of (1) 125% multiplied by (2) the greatest closing sale price of the Common Stock on any Trading Day during the period commencing on the date immediately preceding such Bankruptcy Triggering Event and ending on the date the Company pays the entire payment required, provided that a Holder may, in its sole discretion, waive such right to receive payment upon a Bankruptcy Triggering Event, in whole or in part, and any such waiver will not affect any other rights of such Holder or any other Holder hereunder, including any other rights in respect of such Bankruptcy Triggering Event or any right to conversion (or Alternate Conversion), as applicable.

 

Voting Rights. The holders of the Series C Preferred Stock have no voting power and no right to vote on any matter at any time, either as a separate series or class or together with any other series or class of share of capital stock, and are not entitled to call a meeting of such holders for any purpose nor are they entitled to participate in any meeting of the holders of Common Stock, except as provided in the Certificate of Designations (or as otherwise required by applicable law).

 

Covenants. The Certificate of Designations contains a variety of obligations on the Company’s part not to engage in specified activities, which are typical for transactions of this type. In particular, the Company will not, and will cause the Company’s subsidiaries to not, redeem, repurchase or declare any dividend or distribution on any of its capital stock (other than as required under the Certificate of Designations). In addition, the Company will not issue any preferred stock or issue any other securities that would cause a breach or default under the of Certificate of Designations or PIPE Warrants.

 

Ownership Limitation. In no event may any Preferred Shares be converted (or PIPE Warrants be exercised) and shares of Common Stock be issued to any holder if after giving effect to the issuance of shares of Common Stock upon such conversion of the Preferred Shares (or exercise of the PIPE Warrants), the holder (together with its affiliates, if any) would beneficially own more than 4.99% of the outstanding shares of Common Stock, which we refer to herein as the “PIPE Blocker”). The PIPE Blocker may be raised or lowered to any other percentage not in excess of 9.99% at the option of the applicable holder of the Preferred Shares (or PIPE Warrants), except that any raise will only be effective upon 61-days’ prior notice to the Company.

 

Exchange Right. If the Company or any of its Subsidiaries consummates any Subsequent Placement (other than with respect to Excluded Securities (as defined in the Securities Purchase Agreement)), and a holder elects in writing to the Company to participate in such Subsequent Placement, each such holder may, at the option of such holder as elected in writing to the Company, exchange all, or any part, of the Preferred Shares of such holder into the securities in such Subsequent Placement (with the aggregate amount of such securities to be issued in such exchange equal to such aggregate amount of such securities with a purchase price valued at 120% of the Conversion Amount of the Preferred Shares delivered by such holder in exchange therefor); provided that any such exchange will be subject to all applicable Nasdaq restrictions.

 

Reservation Requirements. So long as any Series C Preferred Stock remains outstanding, the Company will at all times reserve at least 150% of the number of shares of Common Stock as will from time to time be necessary to effect the conversion of all Preferred Shares then outstanding.

 

Conditions Precedent to Closing: As set forth in the Securities Purchase Agreement, the obligations of each party to consummate the PIPE Financing are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated by the Committed Equity Line of Credit (“ELOC”), described below under the caption “Common Stock Purchase Agreement”.

 

 

PIPE Warrants

 

Exercise Price. The exercise price of the PIPE Warrants is $4.38, the Nasdaq Minimum Price (as defined below.) The exercise price is subject to adjustment for stock splits, combinations and similar events, and, in the event of stock dividends and splits, the number of shares of Common Stock issuable upon the exercise of the Warrant also will be adjusted so that the aggregate exercise price will be the same immediately before and immediately after any such adjustment.

 

Exercise Price Adjustments. If on an Adjustment Date, the exercise price then in effect is greater than the Market Price then in effect (the “Warrant Adjustment Price”), the exercise price will automatically lower to the Warrant Adjustment Price. As used herein, “Market Price” means, with respect to any Adjustment Date, the greater of (x) the Floor Price and (y) the lowest closing price of the Common Stock on the Principal Market on any Trading Day during the five (5) Trading Day period ended on, and including, the Trading Day ended immediately prior to such applicable Adjustment Date (each, a “Market Price Measuring Period”). All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such applicable Market Price Measuring Period. Only downward adjustments will be made. 

 

Adjustments for Dilutive Issuances or Variable Price Securities. If and whenever the Company grants, issues or sells (or enters into any agreement to grant, issue or sell), or pursuant to the provisions of the Warrant is deemed to have done any of the foregoing, but excluding any Excluded Securities granted, issued or sold or deemed to have been granted, issued or sold any shares of Common Stock for a consideration price per share (the “Warrant New Issuance Price”) less than a price equal to the exercise price in effect immediately prior to such granting, issuance or sale (the foregoing a “Warrant Dilutive Issuance”), then, immediately after such Warrant Dilutive Issuance, the exercise price then in effect will be reduced to an amount equal to the Warrant New Issuance Price.

 

Additionally, if the Company grants, issues or sells (or enters into any agreement to grant, issue or sell) securities at a Variable Price, the warrant holder shall have the right, but not the obligation, in its sole discretion to exercise the PIPE Warrants at the Variable Price.

 

Exercise Period. The PIPE Warrants are exercisable beginning six months after the issuance date (the “Initial Exercisability Date”) and expiring on the third anniversary of the Initial Exercisability Date. The PIPE Warrants require “buy-in” payments to be made by us for failure to deliver any shares of Common Stock issuable upon exercise.

 

Cashless Exercise. If at the time of exercise of the PIPE Warrants, there is no effective registration statement registering the shares of the Company Common Stock underlying the PIPE Warrants, such PIPE Warrants may be exercised on a cashless basis pursuant to their terms.

 

Purchase Rights; Participation Rights. If the Company issues options, convertible securities, warrants, shares, or similar securities to holders of the Company shares of the Company Common Stock, each Warrant holder has the right to acquire the same as if the holder had exercised its Warrant. The holders of the PIPE Warrants are entitled to receive any dividends paid or distributions made to the holders of the Company’s shares of Common Stock on an “as if converted” basis.

 

Fundamental Transactions. The PIPE Warrants prohibit the Company from entering into specified fundamental transactions unless the successor entity assumes all of the Company obligations under the PIPE Warrants under a written agreement before the transaction is completed. Upon specified corporate events, a Warrant holder will thereafter have the right to receive upon an exercise such shares, securities, cash, assets or any other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event had the Warrant been exercised immediately prior to the applicable corporate event. When there is a transaction involving specified changes of control, a Warrant holder will have the right to force the Company to repurchase the holder’s Warrant for a purchase price in cash equal to the Black Scholes value, as calculated under the PIPE Warrants, of the then unexercised portion of the Warrant.

 

 

USE OF PROCEEDS

 

We will receive the proceeds from any exercise of the PIOs or the PIPE Warrants for cash, but not from the net exercise of any PIOs or PIPE Warrants on a cashless basis or from the resale of any shares of Common Stock by the Selling Stockholders pursuant to this prospectus or the sale of the shares of Common Stock issuable upon the exercise of the PIOs or the PIPE Warrants.

 

Pursuant to the Amended and Restated Forbearance Agreement, dated September 19, 2024, between the Company and Veru, we are required to pay to Veru 20% of the net proceeds received from the exercise of any PIOs or PIPE Warrants to pay down our obligations to Veru. Any proceeds we receive from the exercise of the PIOs or the PIPE Warrants, net of our obligations to Veru, will be used for general corporate and working capital or for other purposes that the Board, in its good faith, deems to be in the best interest of the Company. No assurances can be given that any of such PIOs or PIPE Warrants will be exercised or exercised for cash.

 

DETERMINATION OF OFFERING PRICE

 

The Selling Stockholders will offer Common Stock at the prevailing market prices or a privately negotiated price as it may determine from time to time.

 

The offering price of our Common Stock to be sold by the Selling Stockholders does not necessarily bear any relationship to our book value, assets, past operating results, financial condition, or any other established criteria of value. The facts considered in determining the offering price were our financial condition and prospects, our limited operating history and the general condition of the securities market.

 

In addition, there is no assurance that our Common Stock will trade at market prices in excess of the offering price as prices for our Common Stock in any public market will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity.

 

 

DESCRIPTION OF CAPITAL STOCK

 

General

 

Our Amended and Restated Certificate of Incorporation authorizes the issuance of up to 250,000,000 shares of Common Stock, $0.00001 par value per share, and 10,000,000 shares of preferred stock, $0.00001 par value per share. As of the date of this prospectus, we have 8,294,734 shares of Common Stock outstanding, and 3,499 shares of Series C Preferred Stock issued and outstanding. Our shares of Common Stock are held of record by approximately 37 stockholders.

 

Common Stock

 

Our Common Stock is listed on the Nasdaq Capital Market under the symbol “ONCO.”

 

Under the terms of our Amended and Restated Certificate of Incorporation, holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. The holders of outstanding shares of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times and in such amounts as our Board from time to time may determine. Our Common Stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of our company, the assets legally available for distribution to stockholders are distributable ratably among the holders of our Common Stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. The rights, preferences and privileges of holders of Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

 

Preferred Stock and Warrants

 

Under the terms of our Amended and Restated Certificate of Incorporation, our Board is authorized, without further action by the stockholders, to establish one or more class or series, and fix the relative rights and preferences of the company’s undesignated capital stock.

 

For the material terms of the Series C Preferred Stock and the PIPE Warrants, see “PIPE Financing.”

 

Anti-Takeover Effects of Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws

 

Some provisions of Delaware law, our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.

 

These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our Board. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.

 

Delaware Anti-Takeover Statute

 

We are subject to Section 203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be “interested stockholders” from engaging in a “business combination” with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the Board.

 

 

Choice of Forum

 

Our Amended and Restated Certificate of Incorporation provides that, unless we consent in writing to an alternative forum, to the fullest extent permitted by law, that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty and certain other actions may be brought only in the Court of Chancery in the State of Delaware, except any action (A) as to which the Court of Chancery in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or (C) for which the Court of Chancery does not have subject matter jurisdiction. If an action is brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder’s counsel. Although we believe this provision benefits us by providing increased consistency in the application of law in the types of lawsuits to which it applies, a court may determine that this provision is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against our directors and officers.

 

Our Amended and Restated Certificate of Incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law, subject to certain exceptions. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, our Amended and Restated Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the rules and regulations promulgated thereunder. We note, however, that there is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section 22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our Common Stock is Continental Stock Transfer & Trust Company. The Transfer Agent’s address is 1 State Street, 30^th Floor, New York, New York 10004.

 

Listing

 

Our Common Stock is traded on The Nasdaq Capital Market under the trading symbol “ONCO.”

 

Elimination of Monetary Liability for Officers and Directors

 

Our Amended and Restated Certificate of Incorporation incorporates certain provisions permitted under the Delaware General Corporation Law (“DGCL”) relating to the liability of directors. The provisions eliminate a director’s liability for monetary damages for a breach of fiduciary duty, including gross negligence, except in circumstances involving certain wrongful acts, such as the breach of director’s duty of loyalty or acts or omissions, which involve intentional misconduct or a knowing violation of law. These provisions do not eliminate a director’s duty of care. Moreover, these provisions do not apply to claims against a director for certain violations of law, including knowing violations of federal securities law. Our Amended and Restated Certificate of Incorporation also contains provisions to indemnify the directors, officers, employees or other agents to the fullest extent permitted by the DGCL. We believe that these provisions will assist us in attracting and retaining qualified individual to serve as directors.

 

Indemnification of Officers and Directors

 

Our Amended and Restated Certificate of Incorporation also contains provisions to indemnify the directors, officers, employees or other agents to the fullest extent permitted by the DGCL. These provisions may have the practical effect in certain cases of eliminating the ability of stockholders to collect monetary damages from directors. We are also a party to indemnification agreements with each of our directors. We believe that these provisions will assist us in attracting or retaining qualified individuals to serve as our directors.

 

 

SELLING STOCKHOLDERS

 

The shares of Common Stock being offered by the Selling Stockholders are those previously issued to the Selling Stockholders, and those issuable to the Selling Stockholders, upon exercise of the PIOs or PIPE Warrants or conversion of the Series C Preferred Stock. We are registering the shares of Common Stock in order to permit the Selling Stockholders to offer the shares for resale from time to time. Except for the ownership of the shares of Common Stock underlying the PIOs, the Selling Stockholders have not had any material relationship with us within the past three years; provided, however, that:

 

●

each of Michael Vasinkevich, Noam Rubinstein, Craig Schwabe and Charles Worthman are associated persons of H.C. Wainwright & Co., LLC (“Wainwright”), which served as our placement agent in connection with prior offerings consummated in August 2022, August 2023 and July 2024, for each of which Wainwright received compensation.

 

●

each of Romy Seth and Lacarya Scott are associated persons of Tungsten Advisors (through its Broker-Dealer, Finalis Securities LLC) (“Tungsten”), and served as our financial advisor in connection with the December 2023 private placement of Common Stock and Pre-Funded Warrants and the October 2024 private placement of Series C Preferred Stock and PIPE Warrants, for each of which Tungsten received compensation.

 

The table below lists the Selling Stockholders and other information regarding the beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder) of the shares of Common Stock by each of the Selling Stockholders. The second column lists the number of shares of Common Stock beneficially owned by the Selling Stockholders, based on their respective ownership of shares of Common Stock, Series C Preferred Stock, PIOs and PIPE Warrants, as of October 25, 2024, assuming conversion of the shares of Series C Preferred Stock and exercise of the PIOs and/or PIPE Warrants held by each such Selling Stockholder on that date but taking account of any limitations on conversion and exercise set forth therein.

 

 The third column lists the shares of Common Stock being offered by this prospectus by the Selling Stockholders and does not take in account any limitations on (i) conversion of the Series C Preferred Stock set forth therein or (ii) exercise of the PIOs and/or PIPE Warrants set forth therein.

 

In accordance with the terms of a registration rights agreement with the holders of the Series C Preferred Stock and the PIPE Warrants, this prospectus generally covers the resale of 150% of the sum of (i) the maximum number of shares of Common Stock issuable upon conversion of all the Series C Preferred Stock then outstanding (assuming for purposes hereof that (x) the shares of Series C Preferred Stock are convertible at the Alternate Conversion Price then in effect assuming an Alternate Conversion Date (as defined in the Certificate of Designations) as of such applicable date of determination and (y) any such conversion shall not take into account any limitations on the conversion of the Series C Preferred Stock set forth in the Certificate of Designations and (ii) the maximum number of shares of Common Stock issuable upon exercise of the PIPE Warrants (without regard to any limitations on conversion or exercise contained therein solely for the purpose of such calculation) at a Conversion Price or exercise price (as the case may be) calculated as of the trading day immediately preceding the date this registration statement was initially filed with the SEC. Because the Conversion Price of the Series C Preferred Stock and the exercise price of the PIPE Warrants may be adjusted, the number of shares that will actually be issued may be more or less than the number of shares being offered by this prospectus. The fourth column assumes the sale of all of the shares offered by the Selling Stockholders pursuant to this prospectus.

 

Under the terms of the PIOs held by certain Selling Stockholders, a Selling Stockholder may not exercise the PIOs to the extent such exercise would cause such Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of Common Stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding Common Stock following such exercise, excluding for purposes of such determination shares of Common Stock issuable upon exercise of such PIOs which have not been exercised. The number of shares in the second and fourth columns do not reflect this limitation.

 

Under the terms of the Series C Preferred Stock and the PIPE Warrants, a Selling Stockholder may not convert the Series C Preferred Stock or exercise the PIPE Warrants to the extent (but only to the extent) such Selling Stockholder or any of its affiliates would beneficially own a number of shares of our Common Stock which would exceed 4.99% of the outstanding shares of the Company (the “Maximum Percentage”). The number of shares in the second column reflects these limitations. The Selling Stockholders may sell all, some or none of their shares in this offering.

 

 

The Selling Stockholders may sell all, some or none of their shares in this offering. See “Plan of Distribution.”

 

Name of Selling Shareholder		Number of shares of Common Stock Beneficially Owned Prior to Offering				Percentage of shares of Common Stock Beneficially Owned Prior to Offering(1)				Maximum Number of shares of Common Stock to be Sold Pursuant to this Prospectus				Number of shares of Common Stock Beneficially Owned After Offering				Percentage of shares of Common Stock Beneficially Owned After Offering(1)
Sabby Volatility Warrant Master Fund, Ltd.(2)			186,465	(3)			2.2	%			186,465				0				0	%
Armistice Capital, LLC(4)			372,932	(5)			4.5	%			372,932				0				0	%
Michael Vasinkevich			15,440	(6)			*				8,370				7,070				0	%
Noam Rubinstein			7,585	(6)			*				4,112				3,473				*
Craig Schwabe			813	(6)			*				441				372				*
Charles Worthman			241	(6)			*				131				110				*
Keystone Capital Partners, LLC			435,646	(7)			4.9	%			961,687	(28)			0	(29)			0	%
Jim Fallon			177,963	(8)			2.1	%			288,936	(28)			0	(29)			0	%
Seven Knots, LLC			213,128	(9)			2.5	%			346,295	(28)			0	(29)			0	%
Five Narrow Lane LP			335,392	(10)			4.1	%			577,338	(28)			0	(29)			0	%
First Fire Global Opportunities Fund LLC			177,963	(11)			2.1	%			288,936	(28)			0	(29)			0	%
Pinz Capital Special Opportunities Fund, LP(12)			177,963	(12)			2.1	%			288,936	(28)			0	(29)			0	%
Altos Venture AG(13)			2,695,931				32.5	%			2,695,931				0				0	%
Veru Inc.(14)			130,321				1.6	%			130,321				0				0	%
Ralph Schiess			495,903				6.0	%			495,903				0				0	%
Christian Brühlmann			433,910				5.2	%			433,910				0				0	%
Thomas Cerny(15)			129,673				1.6	%			129,673				0				0	%
Rudolf Aebersold(16)			64,172				*				64,172				0				0	%
Corinne Krek(17)			61,977				*				61,977				0				0	%
ETH Zurich(18)			49,072				*				49,072				0				0	%
Schoepflin Trust(19)			325,901				3.9	%			325,901				0				0	%
Zürcher Kantonalbank(20)			562,691				6.8	%			562,691				0				0	%
W.A. de Vigier Stiftung(21)			2,453				*				2,453				0				0	%
Labrador Trust(22)			54,653				*				54,653				0				0	%
Andre J. Mueller(23)			277,615				3.3	%			277,615				0				0	%
Davent Holding(24)			50,887				*				50,887				0				0	%
Scablis AG(25)			581,938				7.0				581,938				0				0	%
Romy Seth(26)			372,712				4.5	%			372,712				0				0	%
Finalis Securities LLC(27)			7,147				*				7,147				0				0	%
Lacarya Scott(30)			372,712				4.5	%			372,712				0				0	%
Harry Welten(31)			6,880				*	%			6,880				0				0	%
Helge Lubenow(32)			3,801				*	%			3,801				0				0	%
New Horizon Health Limited(33)			573,080				6.9	%			573,080				0				0	%
Werner Schafer(34)			8,548				*	%			8,548				0				0	%

 

*

Less than 1.0% and greater than 0.0%.

 

(1)

Applicable percentage ownership is based on 8,294,734 shares of our Common Stock outstanding as of October 25, 2024, and based on 11,619,313 shares of our Common Stock outstanding after the offering.

(2)

The securities are directly held by Sabby Volatility Warrant Master Fund, Ltd, a Cayman Islands exempted company (“Sabby”) and may be deemed to be beneficially owned by: (i) Sabby Management, LLC, as investment manager of Sabby and (ii) Hal Mintz, as manager of Sabby Management, LLC. The address of Sabby is Governors Square, Bldg 4, 2nd Floor, 23 Lime Tree Bay Avenue, P.O. Box 32315, Grand Cayman KY1-1209, Cayman Islands. Each of Sabby Management, LLC and Hal Mintz disclaims beneficial ownership over the securities listed except to the extent of their pecuniary interest therein. The address of Sabby Volatility Warrant Master Fund, Ltd. is Captiva (Cayman) Ltd, Governors Square, Bldg 4, 2nd Floor, 23 Lime Tree Bay Avenue, P.O. Box 32315, Grand Cayman KY1-1209, Cayman Islands.

(3)

Consists of shares of Common Stock underlying Inducement PIOs held by the Selling Stockholder. The aforementioned Inducement PIOs are subject to certain beneficial ownership limitations that prohibit the holder from exercising any portion of them if such exercise would result in the holder owning a percentage of our outstanding Common Stock exceeding the applicable ownership limitation after giving effect to the issuance of Common Stock in connection with the holder’s exercise of any portion of an Inducement PIO.

(4)

The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (“Armistice Capital”), as the investment manager of Armistice; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.

 

 

(5)

Consists of shares of Common Stock underlying Inducement PIOs held by the Selling Stockholder. The aforementioned Inducement PIOs are subject to certain beneficial ownership limitations that prohibit Armistice from exercising any portion of them if such exercise would result in Armistice owning a percentage of our outstanding Common Stock exceeding the applicable ownership limitation after giving effect to the issuance of Common Stock in connection with Armistice’s exercise of any portion of an Inducement PIO.

(6)

Consists of shares of Common Stock underlying Placement Agent Inducement PIOs issued on July 15, 2024.

Each of the Selling Stockholders is affiliated with H.C. Wainwright & Co., LLC, a registered broker dealer with a registered address of H.C. Wainwright & Co., LLC, 430 Park Ave, 3rd Floor, New York, NY 10022, and has sole voting and dispositive power over the securities held. The number of shares beneficially owned prior to this offering consist of shares of Common Stock issuable upon exercise of the Placement Agent Inducement PIOs, which were received as compensation in connection with the consummation of prior offerings. The Selling Stockholder acquired the Placement Agent Inducement PIOs in the ordinary course of business and, at the time the Placement Agent Inducement PIOs were acquired, the Selling Stockholder had no agreement or understanding, directly or indirectly, with any person to distribute such securities.

(7)

This column lists the number of shares of Common Stock beneficially owned by this Selling Stockholder as of October 25, 2024 after giving effect to the Maximum Percentage (as defined above). Without regard to the Maximum Percentage, as of October 25, 2024, this Selling Securityholder would beneficially own an aggregate of 761,935 shares of Common Stock underlying the Series C Preferred Stock, convertible at an Alternate Conversion Price of $2.8152 per share, all of which shares are being registered for resale under this prospectus. The shares of Common Stock to be offered pursuant to this prospectus includes 199,752 shares issuable upon exercise of PIPE Warrants, all of which shares are being registered for resale under this prospectus, that will not be exercisable until on or after April 3, 2025 and, as such, are excluded from such holder’s beneficial ownership. Keystone Capital Partners LLC is managed by RANZ Group LLC. Frederic Zaino, the Managing Member of RANZ Group LLC, may be deemed to have investment discretion and voting power over the shares held by Keystone Capital Partners LLC. RANZ Group LLC and Mr. Zaino each disclaim any beneficial ownership of these shares. The address of the selling stockholder is 139 Fulton Street, Suite 412, New York, NY 10038.

(8)

This column lists the number of shares of Common Stock beneficially owned by this Selling Stockholder as of October 25, 2024. As of October 25, 2024, this Selling Securityholder beneficially owns an aggregate of 177,963 shares of Common Stock underlying the Series C Preferred Stock, convertible at an Alternate Conversion Price of $2.8152 per share, all of which shares are being registered for resale under this prospectus. The shares of Common Stock to be offered pursuant to this prospectus includes 110,973 shares issuable upon exercise of PIPE Warrants, all of which shares are being registered for resale under this prospectus, that will not be exercisable until on or after April 3, 2025 and, as such, are excluded from such holder’s beneficial ownership. The address of the selling stockholder is 137 West 83rd Street Apt 5W, New York, NY 10024.

(9)

This column lists the number of shares of Common Stock beneficially owned by this Selling Stockholder as of October 25, 2024. As of October 25, 2024, this Selling Securityholder beneficially owns an aggregate of 213,128 shares of Common Stock underlying the Series C Preferred Stock, convertible at an Alternate Conversion Price of $2.8152 per share, all of which shares are being registered for resale under this prospectus. The shares of Common Stock to be offered pursuant to this prospectus includes 133,167 shares issuable upon exercise of PIPE Warrants, all of which shares are being registered for resale under this prospectus, that will not be exercisable until on or after April 3, 2025 and, as such, are excluded from such holder’s beneficial ownership. Marissa Welner, the Manager of Seven Knots, LLC, holds voting and, as such, are excluded from such holder’s dispositive power over the shares of Common Stock held by this Selling Stockholder. Ms. Welner disclaims any beneficial ownership of these shares. The business address of Seven Knots, LLC is 400 E 66th St., #8D, New York, NY 10065.

(10)

This column lists the number of shares of Common Stock beneficially owned by this Selling Stockholder as of October 25, 2024. As of October 25, 2024, this Selling Securityholder beneficially owns an aggregate of 355,392 shares of Common Stock underlying the Series C Preferred Stock, convertible at an Alternate Conversion Price of $2.8152 per share, all of which shares are being registered for resale under this prospectus. The shares of Common Stock to be offered pursuant to this prospectus includes 221,946 shares issuable upon exercise of PIPE Warrants, all of which shares are being registered for resale under this prospectus, that will not be exercisable until on or after April 3, 2025 and, as such, are excluded from such holder’s beneficial ownership. Each of Arie Rabinowitz and Joseph Hammer may be deemed to have investment discretion and voting power over the shares held by Five Narrow Lane LP. Each of Messrs. Rabinowitz and Hammer disclaims any beneficial ownership of these shares except to the extent of his pecuniary interest therein. The address of the selling stockholder is 510 Madison Ave, Ste: 1400, New York, NY 10022.

(11)

This column lists the number of shares of Common Stock beneficially owned by this Selling Stockholder as of October 25, 2024. As of October 25, 2024, this Selling Securityholder beneficially owns an aggregate of 177,963 shares of Common Stock underlying the Series C Preferred Stock, convertible at an Alternate Conversion Price of $2.8152 per share, all of which shares are being registered for resale under this prospectus. The shares of Common Stock to be offered pursuant to this prospectus includes 110,973 shares issuable upon exercise of PIPE Warrants, all of which shares are being registered for resale under this prospectus, that will not be exercisable until on or after April 3, 2025 and, as such, are excluded from such holder’s beneficial ownership. Eliezer Fireman may be deemed to have investment discretion and voting power over the shares held by First Fire Global Opportunities Fund LLC. Mr. Fireman disclaims any beneficial ownership of these shares except to the extent of his pecuniary interest therein. The address of the selling stockholder is 1040 1st Ave Suite 190, New York, NY 10022.

 

 

(12)

This column lists the number of shares of Common Stock beneficially owned by this Selling Stockholder as of October 25, 2024. As of October 25, 2024, this Selling Securityholder beneficially owns an aggregate of 177,963 shares of Common Stock underlying the Series C Preferred Stock, convertible at an Alternate Conversion Price of $2.8152 per share, all of which shares are being registered for resale under this prospectus. The shares of Common Stock to be offered pursuant to this prospectus includes 110,973 shares issuable upon exercise of PIPE Warrants, all of which shares are being registered for resale under this prospectus, that will not be exercisable until on or after April 3, 2025 and, as such, are excluded from such holder’s beneficial ownership. The address of the selling stockholder is 27 Hospital Road,George Town, Grand Cayman, KY1-9008, Cayman Islands.

(13)

Each of Tobias Fischli, Walter Fischli, Christoph Fischli and Roger Widmer may be deemed to have investment discretion and voting power over the shares held by Altos Venture, Ltd. Each of Messrs. T. Fischli, W. Fischli, C. Fischli and Widmer disclaims any beneficial ownership of these shares except to the extent of his pecuniary interest therein. The address of the selling stockholder is Obertorweg 64, CH-4123 Allschwil CH-4123, Switzerland.

(14)

Dr. Mitchell Steiner is the Chairman, President and CEO of Veru Inc., and Michele Greco is the CFO of Very Inc. As such, each of Dr. Steiner and Ms. Greco may be deemed to have investment discretion and voting power over the shares held by Very Inc.. Each of Dr. Steiner and Ms. Greco disclaims any beneficial ownership of these shares except to the extent of their pecuniary interest therein. The address of the selling stockholder is 48 NW 25th Street, Miami, FL 33127.

(15)

The address of the selling stockholder is Trüelmatt 2a, Goldiwil Thun., 3624, Switzerland.

(16)

The address of the selling stockholder is Michelstrasse 52, Zürich 8049, Switzerland.

(17)

The address of the selling stockholder is Wiesenrain 15, Herrliberg 8704, Switzerland.

(18)

Professor Dr. Vanessa Wood may be deemed to have investment discretion and voting power over the shares held by ETH Zurich, Ltd. Prof. Dr. Wood disclaims any beneficial ownership of these shares except to the extent of her pecuniary interest therein. The address of the selling stockholder is Remistrasse 101, Zürich 8092, Switzerland.

(19)

Each of Hans W. Schoepflin and Kristopher Ostrander may be deemed to have investment discretion and voting power over the shares held by Schoepflin Trust. Each of Messrs. Schoepflin and Ostrander disclaims any beneficial ownership of these shares except to the extent of his pecuniary interest therein. The address of the selling stockholder is C/O Cica Inc., 7979 Ivanhoe Ave. Ste 460, La Jolla, CA 92037-4564.

(20)

The address of the selling stockholder is C/O Zurcher Kantonalbank, Bahnhofstrasse 9, Zurich CH-8001, Switzerland.

(21)

Each of Hanna Byland and Celine Bedu may be deemed to have investment discretion and voting power over the shares held by W.A. De Vigier Stiftung. Each of Ms. Byland and Ms. Bedu disclaims any beneficial ownership of these shares except to the extent of her pecuniary interest therein. The address of the selling stockholder is Untere Steingrubenstrasse 25, Solothurn CH-4500, Switzerland.

(22)

Kristopher Ostrander may be deemed to have investment discretion and voting power over the shares held by Labrador Trust. Mr. Ostrander disclaims any beneficial ownership of these shares except to the extent of his pecuniary interest therein. The address of the selling stockholder is C/O The Labrador Trust, 270 Pearl Ave. Apt 103, Jackson, WY 83001-8166.

(23)

The address of the selling stockholder is Avenue Montjoie 200, Bruxelles B-1180, Switzerland.

(24)

Thomas Knecht may be deemed to have investment discretion and voting power over the shares held by Davent Holdings. Mr. Knecht disclaims any beneficial ownership of these shares except to the extent of his pecuniary interest therein. The address of the selling stockholder is Schilfmattweg 7, Zug CH-6300, Switzerland.

(25)

Raymond Fehlbaum may be deemed to have investment discretion and voting power over the shares held by Scablis AG. Mr. Fehlbaum disclaims any beneficial ownership of these shares except to the extent of his pecuniary interest therein. The address of the selling stockholder is Klünenfeldstrasse 22, Birsfelden CH-4127, Switzerland.

(26)

The address of the selling stockholder is 1182 Broadway, 13A New York, NY 10001.

(27)

Charles Bradley Ziemba is the Chief Executive Officer and Chief Compliance Officer of Finalis Securities LLC, and as such may be deemed to have investment discretion and voting power over the shares held by Finalis Securities LLC. Mr. Ziemba disclaims any beneficial ownership of these shares except to the extent of his pecuniary interest therein. The address of the selling stockholder is 228 Park Avenue South, Suite 85550, New York, NY 10003.

(28)

For the purposes of the calculations of our Common Stock to be sold pursuant to the prospectus we are assuming (i) an event of default under the Certificate of Designations has not occurred, and the issuance of 150% of the shares of our Common Stock underlying the Series C Preferred Stock, converted in full at an Alternate Conversion Price of $2.8152 per share without regard to any limitations set forth therein, and (ii) the issuance of 150% of the shares of our Common Stock underlying the PIPE Warrant, exercised in full at an exercise price of $4.38 without regard to any limitations set forth therein.

(29)

Represents the amount of shares that will be held by this Selling Stockholder after completion of this offering based on the assumptions that (a) all Commons Stock underlying the Series C Preferred Stock and PIPE Warrants registered for sale by the registration statement of which this prospectus is part of will be sold, and (b) no other shares of Common Stock are acquired or sold by this Selling Stockholder prior to completion of this offering. However, this Selling Stockholder is not obligated to sell all or any portion of the shares of our Common Stock offered pursuant to this prospectus.

(30)

The address of the selling stockholder is 3951 Stansbury Avenue Sherman Oaks, CA 91423.

(31)

The address of the selling stockholder is Kunzenbadstrasse 5, Zofingen 4800, Switzerland.

(32)

The address of the selling stockholder is Steinfurther Hauptstrasse 36D, Bad Nauheim 61231, Germany.

(33)

Yiyou Chen may be deemed to have investment discretion and voting power over the shares held by New Horizon Health Limited. Yiyou Chen disclaims any beneficial ownership of these shares except to the extent of their pecuniary interest therein. The address of the selling stockholder is Cricket Square, Hutchins Drive, P.O. Box 1681, Grand Cayman KY 1-1111, Cayman Islands.

(34)

The address of the selling stockholder is Paukinestr. 11, Wiesbaden 65189, Germany.

 

 

PLAN OF DISTRIBUTION

 

We are registering the shares of Common Stock issuable upon conversion of the Series C Preferred Stock and exercise of the PIOs and PIPE Warrants to permit the resale of these shares of Common Stock by the holders of the Series C Preferred Stock, the PIOs and the PIPE Warrants from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling Stockholders of the shares of Common Stock, although we will receive the exercise price of any PIOs and PIPE Warrants not exercised by the Selling Stockholders on a cashless exercise basis. We will bear all fees and expenses incident to our obligation to register the shares of Common Stock.

 

The Selling Stockholders may sell all or a portion of the shares of Common Stock held by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of Common Stock are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of Common Stock may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions, pursuant to one or more of the following methods:

 

●

on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;

 

●

in the over-the-counter market;

 

●

in transactions otherwise than on these exchanges or systems or in the over-the-counter market;

 

●

through the writing or settlement of options, whether such options are listed on an options exchange or otherwise;

 

●

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

●

block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

 

●

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

 

●

an exchange distribution in accordance with the rules of the applicable exchange;

 

●

privately negotiated transactions;

 

●

short sales made after the date the Registration Statement is declared effective by the SEC;

 

●

broker-dealers may agree with a selling security holder to sell a specified number of such shares at a stipulated price per share;

 

●

a combination of any such methods of sale; and

 

●

any other method permitted pursuant to applicable law.

 

The Selling Stockholders may also sell shares of Common Stock under Rule 144 promulgated under the Securities Act of 1933, as amended, if available, rather than under this prospectus. In addition, the Selling Stockholders may transfer the shares of Common Stock by other means not described in this prospectus. If the Selling Stockholders effect such transactions by selling shares of Common Stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers of the shares of Common Stock for whom they may act as agent or to whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). In connection with sales of the shares of Common Stock or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the shares of Common Stock in the course of hedging in positions they assume. The Selling Stockholders may also sell shares of Common Stock short and deliver shares of Common Stock covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The Selling Stockholders may also loan or pledge shares of Common Stock to broker-dealers that in turn may sell such shares.

 

 

The Selling Stockholders may pledge or grant a security interest in some or all of the Series C Preferred Stock, PIOs, PIPE Warrants or shares of Common Stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of Common Stock from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this prospectus. The Selling Stockholders also may transfer and donate the shares of Common Stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

 

To the extent required by the Securities Act and the rules and regulations thereunder, the Selling Stockholders and any broker-dealer participating in the distribution of the shares of Common Stock may be deemed to be “underwriters” within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the shares of Common Stock is made, a prospectus supplement, if required, will be distributed, which will set forth the aggregate amount of shares of Common Stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the Selling Stockholders and any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers.

 

Under the securities laws of some states, the shares of Common Stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares of Common Stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.

 

There can be no assurance that any Selling Stockholder will sell any or all of the shares of Common Stock registered pursuant to the registration statement, of which this prospectus forms a part.

 

The Selling Stockholders and any other person participating in such distribution will be subject to applicable provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of Common Stock by the Selling Stockholders and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the shares of Common Stock to engage in market-making activities with respect to the shares of Common Stock. All of the foregoing may affect the marketability of the shares of Common Stock and the ability of any person or entity to engage in market-making activities with respect to the shares of Common Stock.

 

We will pay all expenses of the registration of the shares of Common Stock pursuant to the registration rights agreement, estimated to be approximately $84,884 in total, including, without limitation, Securities and Exchange Commission filing fees and expenses of compliance with state securities or “blue sky” laws; provided, however, a Selling Stockholder will pay all underwriting discounts and selling commissions, if any. We will indemnify the Selling Stockholders against liabilities, including some liabilities under the Securities Act in accordance with the registration rights agreements or the Selling Stockholders will be entitled to contribution. We may be indemnified by the Selling Stockholders against civil liabilities, including liabilities under the Securities Act that may arise from any written information furnished to us by the Selling Stockholders specifically for use in this prospectus, in accordance with the related registration rights agreements or we may be entitled to contribution.

 

Once sold under the registration statement, of which this prospectus forms a part, the shares of Common Stock will be freely tradable in the hands of persons other than our affiliates.

 

 

EXPERTS

 

The consolidated balance sheet of Onconetix, Inc. and Subsidiary as of December 31, 2023, and the related consolidated statements of operations and comprehensive loss, convertible redeemable preferred stock and stockholders’ equity (deficit), and cash flows for the year then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report, which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern. Such financial statements have been incorporated herein by reference in this prospectus in reliance on the report of such firm given upon their authority as experts in accounting and auditing.

 

 The consolidated financial statements of Onconetix, Inc., formerly known as Blue Water Vaccines Inc., as of and for the year ended December 31, 2022, appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, have been audited by CBIZ CPAs P.C. (formerly Mayer Hoffman McCann, P.C.), independent registered public accounting firm, as set forth in their report, and have been incorporated herein by reference in this prospectus in reliance upon such report given on the authority of such firm as experts in accounting and auditing, in giving said reports.

 

The financial statements of Proteomedix AG as of December 31, 2022, and 2021 and for each of the two years in the period ended December 31, 2022, which have been incorporated by reference in this prospectus and the registration statement of which it forms a part, have been so included in reliance on the report of BDO AG, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory paragraph regarding Proteomedix AG’s ability to continue as a going concern. Such financial statements and audit report are incorporated by reference to the Company’s Current Report on Form 8-K/A, as filed with the SEC on February 27, 2024.

 

LEGAL MATTERS

 

Ellenoff Grossman & Schole LLP, New York, New York, will pass upon the validity of the securities offered hereby.

 

WHERE YOU CAN FIND MORE INFORMATION

 

We are subject to the informational requirements of the Exchange Act and, in accordance therewith, file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s website at www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at www.onconetix.com. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus.

 

This prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements.

 

 

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

 

The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated, and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 000-52994) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed:

 

(i)

our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on April 11, 2024

 

(ii)

our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the SEC on May 20, 2024, and for the quarter ended June 30, 2024, as filed with the SEC on August 29, 2024;

 

(iii)

Current Reports on Form 8-K filed on each of January 12, 2024, January 19, 2024, January 29, 2024, February 12, 2024, February 13, 2024, February 27, 2024, April 8, 2024, April 26, 2024, May 13, 2024, June 13, 2024, June 14, 2024, July 11, 2024, July 15, 2024, August 7, 2024, September 3, 2024, September 5, 2024, September 11, 2024, September 20, 2024, September 24, 2024, October 3, 2024, October 9, 2024 and October 21, 2024;

 

(iv)

our Definitive Proxy Statement, as filed with the SEC on August 1, 2024, and the supplemental proxy materials filed with the SEC on September 3, 2024; and

 

(v)

the description of our securities registered under Section 12 of the Exchange Act as filed as Exhibit 4.2 on our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on April 11, 2024.

 

You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number:

 

Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, Ohio 45202
(513) 620-4101

 

You may also access the documents incorporated by reference in this prospectus through our website at www.onconetix.com. Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part. The information contained on our website is not part of this prospectus.

 

 

PART II
INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 13. Other Expenses of Issuance and Distribution.

 

Set forth below are estimates (except in the case of SEC registration fees) of the amount of fees and expenses to be incurred in connection with the issuance and distribution of the offered securities, other than underwriting discounts and commissions.

 

SEC registration fee		$	4,883.88
Accounting services			37,500
Legal fees			37,500	*
Miscellaneous			5,000	*
Total		$	84883.88

 

*

Estimated

 

Item 14. Indemnification of Directors and Officers.

 

Section 145 of the DGCL inter alia, empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. Similar indemnity is authorized for such persons against expenses (including attorneys’ fees) actually and reasonably incurred in connection with the defense or settlement of any such threatened, pending or completed action or suit if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and provided further that (unless a court of competent jurisdiction otherwise provides) such person shall not have been adjudged liable to the corporation. Any such indemnification may be made only as authorized in each specific case upon a determination by the stockholders or disinterested directors or by independent legal counsel in a written opinion that indemnification is proper because the indemnitee has met the applicable standard of conduct.

 

Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies insuring our officers and directors against certain liabilities for actions taken in such capacities, including liabilities under the Securities Act.

 

Section 102(b)(7) of the DGCL permits a corporation to include in its certificate of incorporation a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL (relating to unlawful payment of dividends and unlawful stock purchase or redemption) or (iv) for any transaction from which the director derived an improper personal benefit.

 

Article 6 of the bylaws of the Company contains provisions which are designed to provide mandatory indemnification of directors and officers of the Company to the full extent permitted by law, as now in effect or later amended. The bylaws further provide that, if and to the extent required by the DGCL, an advance payment of expenses to a director or officer of the Company that is entitled to indemnification will only be made upon delivery to the Company of an undertaking, by or on behalf of the director or officer, to repay all amounts so advanced if it is ultimately determined that such director is not entitled to indemnification.

 

 

Item 16. Exhibits and Financial Statement Schedules.

 

				Incorporated by Reference
Exhibit No.		Description		Form		Exhibit		Filing Date
2.1		Share Exchange Agreement, dated December 15, 2023, by and among the Company, Proteomedix, Thomas Meier and the Sellers.		8-K		2.1		December 21, 2023
3.1		Amended and Restated Certificate of Incorporation filed with Delaware Secretary of State on February 23, 2022.		8-K		3.1		February 24. 2022
3.2		Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation		8-K		3.1		April 24, 2023
3.3		Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation.		8-K		3.1		December 21, 2023
3.4		Fourth Amended and Restated Bylaws of the Company.		8-K		3.2		December 21, 2023
3.5		Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024.		8-K		3.1		September 20, 2024
3.6		Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024.		8-K		3.1		September 24, 2024
4.1		Specimen Common Stock Certificate.		S-1		4.1		October 8, 2021
4.2		Description of Registered Securities.		10-K		4.2		April 11, 2024
4.3		Certificate of Designation of Series A Preferred Stock.		8-K		3.1		October 3, 2023
4.4		Certificate of Designation of Series B Convertible Preferred Stock.		8-K		4.1		December 21, 2023
4.5		Form of Inducement PIO.		8-K		4.1		August 3, 2023
4.6		Form of Inducement PIO.		8-K		4.1		July 11, 2024
4.7		Form of Altos Warrants.		8-K		4.1		September 24, 2024
4.8		Form of Warrant.		8-K		4.1		October 3, 2024
4.9		Certification of Designation of Series C Preferred Stock.		8-K		3.1		October 3, 2024
5.1**		Opinion of Ellenoff Grossman & Schole LLP as to the legality of the securities being registered.
10.1		2019 Equity Incentive Plan.		S-1		10.1		October 8, 2021
10.2		2022 Equity Incentive Plan.		S-1/A		10.2		November 29, 2021
10.3		2019 Equity Incentive Plan Form of Stock Option Grant Agreement.		S-1		10.3		October 8, 2021
10.4		2022 Equity Incentive Plan Form of Incentive Stock Option Agreement (Employee).		S-1/A		10.4		January 6, 2022
10.5		2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Consultant).		S-1/A		10.5		January 6, 2022
10.6		2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Non-Employee Director).		S-1/A		10.6		January 6, 2022
10.7		2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Employee).		S-1/A		10.7		January 6, 2022
10.8		Lease Agreement, dated as of April 29, 2021, between the Registrant and Regus Management Group, LLC.		S-1		10.11		October 8, 2021
10.9		Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of July 19, 2019.		S-1		10.12		October 8, 2021

  

 

10.10		Project Addendum 1 to Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of October 9, 2019.		S-1		10.13		October 8, 2021
10.11		Letter Agreement between the Registrant and Ology Bioservices, Inc., dated as of January 9, 2020.		S-1		10.14		October 8, 2021
10.12		Project Addendum II to Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of May 21, 2021		S-1		10.15		October 8, 2021
10.13		Form of Employment Agreement with Joseph Hernandez		S-1		10.16		October 8, 2021
10.14		Form of Employment Agreement with Erin Henderson		S-1		10.17		October 8, 2021
10.15		Form of Employment Agreement with Jon Garfield.		S-1		10.18		October 8, 2021
10.16		Form of Employment Agreement with Neil Campbell.		8-K		10.1		October 10, 2023
10.17		Form of Employment Agreement with Bruce Harmon.		8-K		10.2		October 10, 2023
10.18		Form of Employment Agreement with Ralph Schiess.		10-K		10.21		April 11, 2024
10.19		Amendment to Employment Agreement, dated October 15, 2020, by and between Proteomedix and Ralph Schiess.		10-K		10.22		April 11, 2024
10.20		Amendment to Employment Agreement by and between Proteomedix and Ralph Schiess.		10-K		10.23		April 11, 2024
10.21		Form of Employment Agreement with Christian Brühlmann.		10-K		10.24		April 11, 2024
10.22		Amendment to Employment Agreement, dated October 16, 2020, by and between Proteomedix and Christian Brühlmann.		10-K		10.25		April 11, 2024
10.23		Amendment to Employment Agreement by and between Proteomedix and Christian Brühlmann.		10-K		10.26		April 11, 2024
10.24		General Release of Claims, dated October 5, 2023, by and between Jon Garfield and the Company.		8-K		99.1		October 10, 2023
10.25		Release, dated January 10, 2024, by and between the Company and Dr. Neil Campbell.		8-K		99.1		January 12, 2024
10.26		Form of Indemnification Agreement for Directors and Officers.		8-K		10.3		October 10, 2023
10.27		Form of Securities Purchase Agreement, dated as of April 13, 2022, by and among the Company and the Purchasers.		8-K		10.1		April 19, 2022
10.28		Form of Registration Rights Agreement, dated as of April 13, 2022, by and among the Company and the Purchasers.		8-K		10.2		April 19, 2022
10.29		Form of Securities Purchase Agreement, dated as of August 9, 2022, by and among the Company and the Purchasers.		8-K		10.1		August 11, 2022
10.30		Form of Registration Rights Agreement, dated as of August 9, 2022, by and among the Company and the Purchasers.		8-K		10.2		August 11, 2022
10.31		Settlement Agreement and Release, dated October 9, 2022, by and between the Registrant and Boustead Securities, LLC.		10-Q		10.3		November 14, 2022
10.32		Amendment No. 1 to Project Addendum 2 to Master Services Agreement, dated as of April 20, 2022, by and between the Registrant and Ology Bioservices, Inc.		10-Q		10.1		May 13, 2022

 

 

10.33		Amendment #1 to Exclusive License Agreement, dated as of May 11, 2022, by and between the Registrant and St. Jude Children’s Research Hospital, Inc.		10-Q		10.2		May 13, 2022
10.34		Patent & Technology License Agreement, dated November 18, 2022, between the Company and the University of Texas Health Science Center at San Antonio.		10-Q		10.1		May 12, 2023
10.35		Co-Development Agreement, dated February 1, 2023, between the Company and AbVacc, Inc.		10-Q		10.2		May 12, 2023
10.36		At-the-Market Offering Agreement, dated March 29, 2023, between the Company and H.C. Wainwright & Co., LLC.		8-K		1.1		March 29, 2023
10.37		Asset Purchase Agreement, dated April 19, 2023, between the Company and Veru Inc.		8-K		10.1		April 20, 2023
10.38		Amendment to Asset Purchase Agreement, dated September 29, 2023, between the Company and Veru Inc.		8-K		10.1		October 3, 2023
10.39		Form of Non-Competition and Non-Solicitation Agreement, dated April 19, 2023.		8-K		10.1		April 20, 2023
10.40		Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, and the Company.		8-K		10.1		June 14, 2023
10.41		Management Services Agreement, dated June 13, 2023, by and among WraSer, Xspire and the Company.		8-K		10.2		June 14, 2023
10.42		Form of Amendment, dated October 5, 2023, to Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, Legacy-Xspire Holdings, LLC, and the Company.		10-Q		10.14		October 20, 2023
10.43		Exclusive Distribution Agreement, dated September 20, 2023, between the Company and Cardinal Health 105, LLC.		10-Q		10.6		November 17, 2023
10.44		Form of Lock-Up Agreement, dated December 15, 2023, by and among the Company and certain stockholders of Proteomedix.		8-K		10.1		December 21, 2023
10.45		Form of Non-Competition and Non-Solicitation Agreement, dated December 15, 2023, by and among the Company and certain stockholders of Proteomedix.		8-K		10.2		December 21, 2023
10.46		Form of Stockholder Support Agreement, dated December 15, 2023, by and among the Company, Proteomedix, and certain stockholders of Proteomedix		8-K		10.3		December 21, 2023
10.47		Form of Subscription Agreement, dated December 15, 2023, by and among the Company, Proteomedix, and the PMX Investor.		8-K		10.4		December 21, 2023
10.48		Separation Agreement, dated January 17, 2024, between the Company and Erin Henderson.		8-K		10.1		January 19, 2024
10.49		Consulting Agreement, dated January 17, 2024, between the Company and The Aetos Group.		8-K		10.2		January 19, 2024
10.50		Debenture, dated January 23, 2024 issued to the PMX Investor		8-K		10.1		January 29, 2024
10.51		Consulting Agreement, dated January 4, 2024, by and between the Company and Thomas Meier.		8-K		10.1		February 12, 2024

 

 

10.52		License Agreement, dated March 27, 2023, between Proteomedix and Laboratory Corporation of America Holdings.		10-K		10.55		April 11, 2024
10.53		Form of Inducement Letter		8-K		10.1		August 1, 2023
10.54		Form of Letter Agreement.		8-K		10.1		August 3, 2023
10.55		Amendment to Debenture, dated April 24, 2024, issued to the PMX Investor.		8-K		10.2		April 26, 2024
10.56		Forbearance Agreement, dated April 24, 2024, by and between the Company and Veru Inc.		8-K		10.1		April 26, 2024
10.57		Master Research Services Agreement, dated October 1, 2022, by and between Proteomedix AG and Immunovia, AB		S-1/A		10.60		June 25, 2024
10.58		Collaboration Agreement, dated July 19, 2021, by and between Proteomedix AG and New Horizon Health Limited		S-1/A		10.61		June 25, 2024
10.59		Amendment No. 1, dated June 26, 2023, to Collaboration Agreement, dated July 19, 2021, by and between Proteomedix AG and New Horizon Health Limited		S-1/A		10.62		June 25, 2024
10.60		Release Agreement, dated June 10, 2024, between the Company and Bruce Harmon.		8-K		99.1		June 13, 2024
10.61		Consulting Agreement, dated June 10, 2024, between the Company and Karina Fedasz.		8-K/A		10.1		June 14, 2024
10.62		Form of Inducement Letter		8-K		10.1		July 11, 2024
10.63		Amended and Restated Forbearance Agreement between the Company and Veru, dated September 19, 2024		8-K		10.1		September 20, 2024
10.64		Form of Securities Purchase Agreement dated October 2, 2024 relating to the sale of the Series C Preferred Stock and Warrants		8-K		10.1		October 3, 2024
10.65		Form of Registration Rights Agreement dated as of October 2, 2024 relating to the resale of the shares of Common Stock underlying the Series C Preferred Stock and Warrants		8-K		10.2		October 3, 2024
10.66		Form of ELOC Purchase Agreement dated October 2, 2024		8-K		10.3		October 3, 2024
10.67		Form of ELOC Registration Rights Agreement dated October 2, 2024		8-K		10.4		October 3, 2024
16		Letter from EisnerAmper LLP, dated October 21, 2024.		8-K		6.1		October 21, 2024
21		List of Subsidiaries.		10-K		21		April 11, 2024
23.1*		Consent of CBIZ CPAs P.C.				23.1
23.2*		Consent of EisnerAmper LLP.				23.2
23.3*		Consent of BDO AG.				23.3
23.4**		Consent of Ellenoff Grossman & Schole (included as part of Exhibit 5.1 hereto).
24*		Power of Attorney (included on signature page to this Registration Statement).
107*		Filing Fee Table.
101.INS*		XBRL Instance Document.				101.INS*
101.SCH*		XBRL Taxonomy Schema Linkbase Document.				101.SCH*
101.CAL*		XBRL Taxonomy Calculation Linkbase Document.				101.CAL*
101.DEF*		XBRL Taxonomy Definition Linkbase Document.				101.DEF*
101.LAB*		XBRL Taxonomy Labels Linkbase Document.				101.LAB*
101.PRE*		XBRL Taxonomy Presentation Linkbase Document.				101.PRE*
104*		Cover Page Interactive Data File (Embedded as Inline XBRL document and contained in Exhibit 101).				104*

 

*

Filed herewith.

 

**

To be filed by amendment.

 

†

Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

 

#

Certain portions of this exhibit (indicated by “[*]” have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as we have determined they (1) are not material and (2) are the type that the Company treats as private or confidential. The Registrant hereby agrees to furnish a copy of any omitted portion to the SEC upon request.

 

 

Item 17. Undertakings.

 

The undersigned registrant hereby undertakes:

 

(1)

That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(2)

To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(3)

That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

 

(i)

If the registrant is relying on Rule 430B:

 

(A)

Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

 

(B)

Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or

 

(ii)

If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

 

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cincinnati, Ohio, on November 1, 2024.

 

	ONCONETIX, INC.
	By:	/s/ Karina M. Fedasz
	Name:	Karina M. Fedasz
	Title:	Interim Chief Financial Officer

 

KNOW ALL PERSONS BY THESE PRESENTS that each individual whose signature appears below hereby constitutes and appoints each of Ralph Schiess and Karina M. Fedasz as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act of 1933 increasing the number of shares for which registration is sought, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, making such changes in this registration statement as such attorney-in-fact and agent so acting deem appropriate, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done with respect to the offering of securities contemplated by this registration statement, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his, her or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature		Title		Date
/s/ Ralph Schiess		Interim Chief Executive Officer		November 1, 2024
Ralph Schiess		(Principal Executive Officer)
/s/ Karina M. Fedasz		Interim Chief Financial Officer		November 1, 2024
Karina M. Fedasz		(Principal Financial and Accounting Officer)
/s/ James Sapirstein		Chairman of the Board and Director		November 1, 2024
James Sapirstein
/s/ Thomas Meier		Director		November 1, 2024
Thomas Meier
/s/ Timothy Ramdeen		Director		November 1, 2024
Timothy Ramdeen
/s/ Ajit Singh		Director		November 1, 2024
Ajit Singh
/s/ Simon Tarsh		Director		November 1, 2024
Simon Tarsh

 

 

II-7

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in this Registration Statement on Form S-1 and related prospectus of our report dated March 8, 2023, with respect to the consolidated financial statements of Onconetix, Inc. (formerly known as Blue Water Vaccines Inc.) (the “Company”) as of and for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and to the reference to us under the heading “Experts” in the prospectus which is part of this Registration Statement.

 

/s/ CBIZ CPAs P.C.¹

 

Los Angeles, California

November 1, 2024

 

  

1	In certain jurisdictions, CBIZ CPAs P.C. operates under its previous name, Mayer Hoffman McCann P.C.

 

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in this Registration Statement of Onconetix Inc. on Form S-1 to be filed on or about Novemeber 1, 2024 of our report dated April 11, 2024, on our audit of the financial statements as of December 31, 2023 and for the year then ended, which report was included in the Annual Report on Form 10-K filed April 11, 2024. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. We also consent to the reference to our firm under the caption “Experts” in this Registration Statement.

  

/s/ EisnerAmper LLP

 

EISNERAMPER LLP

Iselin, New Jersey

November 1, 2024

 

 

Exhibit 23.3

 

Phone +41 44 444 35 55 www.bdo.ch zurich@bdo.ch

BDO Ltd Schiffbaustrasse 2 8031 Zurich

 

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the incorporation by reference in the Prospectus constituting a part of Onconetix Inc.’s Registration Statement of our report dated February 14, 2024, relating to the financial statements of Proteomedix AG (the Company), appearing in Onconetix Inc’s Current Report on Form 8-K/A filed February 27, 2024. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

 

We also consent to the reference to us under the caption “Experts” in the Prospectus.

 

/s/ Christoph Tschumi		/s/ Marc Furlato
Christoph Tschumi		Marc Furlato
BDO AG
Zurich, Switzerland
November 1, 2024

 

 

 

BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.

Exhibit 107

 

Calculation of Filing Fee Table

 

Form S-1

(Form Type)

 

Onconetix, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

		Security Type		Security Class Title			Fee Calculation or Carry Forward Rule			Amount Registered(1)				Proposed Maximum Offering Price Per Share				Maximum Aggregate Offering Price				Fee Rate				Amount of Registration Fee				Carry Forward Form Type				Carry Forward File Number				Carry Forward Initial effective date				Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward
Newly Registered Securities
Fees to Be Paid		Equity		Common Stock			457(c)				10,586,557	(2)		$	3.01	(3)		$	31,899,942.88				0.00015310			$	4,883.88	(4)
Fees Previously Paid		-		-			-				-				-				-								-
Carry Forward Securities
Carry Forward Securities		-		-			-				-								-												-				-				-				-
		Total Offering Amounts																								$	4,883.88
		Total Fees Previously Paid																									0
		Total Fee Offsets																									--
		Net Fee Due																								$	4,883.88

 

(1)

Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

 

(2)

Represents the sum of (i) up to 559,398 shares of common stock, par value $0.00001 per share (the “Common Stock”) of Onconetix, Inc., a Delaware corporation (the “Company”), issuable upon exercise of common stock preferred investment options issued to Armistice Capital Master Fund Ltd. and Sabby Volatility Warrant Master Fund, Ltd in a warrant inducement transaction (the “Warrant Inducement”), which closed on July 15, 2024; (ii) 13,053 shares of Common Stock issuable upon exercise of common stock preferred investment options issued to H.C. Wainwright & Co., LLC, the Company’s placement agent for the Warrant Inducement, or its designees, on July 15, 2024 in the Warrant Inducement; (iii) 130,321 shares of Common Stock issued to Veru Inc. (“Veru”) following Veru’s election to convert all of the 3,000 shares of Series A preferred stock of the Company issued to it on September 29, 2023; (iv) 6,464,206 shares of Common Stock issued to certain stockholders of the Company who were formerly holders of outstanding capital stock or convertible securities of Proteomedix AG, pursuant to the automatic conversion of all the 2,696,729 shares of Series B preferred stock of the Company on September 24, 2024, (v) 667,451 shares of Common Stock issued to Altos Venture AG, in a private placement transaction and a warrant exercise, which closed on September 24, 2024; and (vi) up to 2,752,128 shares of Common Stock, which represents 150% of the aggregate number of shares of Common Stock issuable upon the conversion or exercise, as applicable, of the 3,499 shares of Series C preferred stock and warrants to purchase 591,856 shares of Common Stock issued to institutional investors in a private placement transaction, which closed on October 2, 2024.

 

(3)

Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the common stock on The Nasdaq Stock Market LLC on October 30, 2024 ($3.01 per share), in accordance with Rule 457(c) of the Securities Act.

 

(4)

Calculated pursuant to Rule 457 of the Securities Act by multiplying the proposed maximum aggregate offering price of securities to be registered by 0.00015310.

 

 

 

 

 

 

---